We are live on ! Find out more
PYXS icon

Pyxis Oncology
PYXS

80 hedge funds and large institutions have $93.1M invested in Pyxis Oncology in 2024 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 21 increasing their positions, 20 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

9,133% more call options, than puts

Call options by funds: $1.66M | Put options by funds: $18K

56% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 16

11% more funds holding

Funds holding: 72 → 80 (+8)

8.29% more ownership

Funds ownership: 39.48% → 47.77% (+8.3%)

5% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 20

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

5% less capital invested

Capital invested by funds: $97.8M → $93.1M (-$4.7M)

Holders
80
Holders Change
+8
Holders Change %
+11.11%
% of All Funds
1.16%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
25
Increased
21
Reduced
20
Closed
16
Calls
$1.66M
Puts
$18K
Net Calls
+$1.64M
Net Calls Change
+$1.3M

Top Buyers

1
BlackRock
BlackRock
New York
+$10.4M
2
BOCH
Blue Owl Capital Holdings
New York
+$4.4M
3
Millennium Management
Millennium Management
New York
+$3.17M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.89M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$2.77M

Top Sellers

1
SC
Stempoint Capital
New York
-$2.49M
2
MIM
Monashee Investment Management
Massachusetts
-$1.89M
3
Goldman Sachs
Goldman Sachs
New York
-$923K
4
HF
HRT Financial
New York
-$592K
5
Jane Street
Jane Street
New York
-$589K
Name Holding Trade Value Shares
Change 		Change in
Stake
DTC
1
Deep Track Capital
Connecticut
$13.8M – – –
LCM
2
Laurion Capital Management
New York
$12.8M – – –
BlackRock
3
BlackRock
New York
$9.22M +$10.4M +2,464,230 +766%
Balyasny Asset Management
4
Balyasny Asset Management
Illinois
$8.48M -$132K -31,382 -1%
Vanguard Group
5
Vanguard Group
Pennsylvania
$6.82M +$2.77M +659,019 +47%
IC
6
Ikarian Capital
Texas
$5.5M – – –
Millennium Management
7
Millennium Management
New York
$4.43M +$3.17M +753,899 +129%
SC
8
Stempoint Capital
New York
$3.98M -$2.49M -591,520 -33%
BOCH
9
Blue Owl Capital Holdings
New York
$3.46M +$4.4M +1,046,025 New
Geode Capital Management
10
Geode Capital Management
Massachusetts
$3.4M +$2.89M +687,590 +202%
State Street
11
State Street
Massachusetts
$2.46M +$2.66M +633,552 +579%
Aberdeen Group
12
Aberdeen Group
United Kingdom
$2.34M – – –
BFM
13
Boothbay Fund Management
New York
$1.63M – – –
SCM
14
Superstring Capital Management
New York
$1.6M -$39.2K -9,316 -2%
HA
15
HHLR Advisors
Cayman Islands
$1.27M – – –
DC
16
Decheng Capital
California
$1.08M – – –
Bank of New York Mellon
17
Bank of New York Mellon
New York
$1.03M +$629K +149,522 +92%
BCM
18
Bridgeway Capital Management
Texas
$816K +$63.1K +15,000 +6%
Deutsche Bank
19
Deutsche Bank
Germany
$789K +$309K +73,390 +44%
N
20
Nuveen
North Carolina
$493K +$627K +149,024 New
Charles Schwab
21
Charles Schwab
California
$430K +$484K +115,237 +793%
Northern Trust
22
Northern Trust
Illinois
$425K +$282K +67,162 +110%
Goldman Sachs
23
Goldman Sachs
New York
$388K -$923K -219,443 -65%
Susquehanna International Group
24
Susquehanna International Group
Pennsylvania
$383K +$194K +46,244 +67%
AGM
25
Alpine Global Management
New York
$382K +$486K +115,514 New
1
2 3 4

PYXS Hedge Fund Activity: Q2 2024 in Review

80 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Pyxis Oncology (PYXS) for Q2 2024, worth a combined $93.1M — down 4.8% from $97.8M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new PYXS positions and 16 closed out — a net gain of 9 holders — while 21 added to existing stakes and 20 trimmed.

The largest buyer was BlackRock, adding an estimated $10.4M. The largest seller was Stempoint Capital, cutting an estimated $2.49M.

  • 80 institutional investors held Pyxis Oncology (PYXS) as of Q2 2024, up from 72 in Q1 2024.
  • Funds reported $93.1M of Pyxis Oncology stock for Q2 2024, down 4.8% quarter-over-quarter.
  • 25 funds opened new Pyxis Oncology positions in Q2 2024 and 16 closed out, a net change of +9 holders.
  • The largest Pyxis Oncology buyer in Q2 2024 was BlackRock, an estimated $10.4M added.
  • The largest Pyxis Oncology seller in Q2 2024 was Stempoint Capital, an estimated $2.49M sold.

Based on aggregated 13F filings for Q2 2024.